(Q45869946)

English

Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice.

scientific article published in November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

0 references

Hidetsugu Asada

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Tsunao Kishida

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Yoshiki Itokawa

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Kakei Yasutomi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Masaharu Shin-Ya

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Satoshi Gojo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Feng De Cui

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Yuji Ueda

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Hisakazu Yamagishi

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Jiro Imanishi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Osam Mazda

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

738-745

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599806%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Clinical applications of electrochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Therapeutic perspectives of in vivo cell electropermeabilization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Antitumor electrochemotherapy: new advances in the clinical protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Bleomycin-mediated electrochemotherapy of basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electroporation therapy: a new approach for the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electrochemotherapy of cutaneous metastases in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electroporation therapy of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electroporation therapy for head and neck cancer including carotid artery involvement

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Interleukin-12 and the regulation of innate resistance and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Polyethylenimine-mediated suicide gene transfer induces a therapeutic effect for hepatocellular carcinoma in vivo by using an Epstein-Barr virus-based plasmid vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Regulation of human cytolytic lymphocyte responses by interleukin-12

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Induction of apoptosis in head-and-neck squamous carcinoma cells by gamma-irradiation and bleomycin is p53-independent

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Highly efficient suicide gene expression in hepatocellular carcinoma cells by epstein-barr virus-based plasmid vectors combined with polyamidoamine dendrimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Significant Antitumor Effects Obtained by Autologous Tumor Cell Vaccine Engineered to Secrete Interleukin (IL)-12 and IL-18 by Means of the EBV/Lipoplex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin alpha2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein-Barr virus (EBV)-based plasmid vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Efficient selection for high-expression transfectants with a novel eukaryotic vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

Successful genetic transduction in vivo into synovium by means of electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

based on heuristic

inferred from DOI database lookup

oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.002

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45869946&oldid=2098844106"